In 2025, the company's leading products included Opdivo, drugs used in the treatment of certain cancers, and Eliquis, an anticoagulant. Those drugs generated **Ìý²¹²Ô»å **** billion U.S. dollars in revenue for the company, respectively.Â
Bristol-Myers Squibb’s company profile
Bristol-Myers Squibb (BMS) is a pharmaceutical company that produces pharmaceuticals and biologics in several therapeutic areas. BMS has experienced increasing revenues, especially among its prioritized brand areas. Despite increasing revenues, the company’s net income has remained variable over time.
The global oncology market
The global oncology market has grown significantly recently, with new therapies being added every year. Bristol-Myers Squibb (BMS) is ranked among the very top pharmaceutical companies based on their global oncology market share. Other leading pharmaceutical companies include Roche and Johnson & Johnson. The top oncology products worldwide based on revenue include Keytruda, Revlimid, and Imbruvica, which are marketed by Merck, BMS, and J&J/AbbVie, respectively.
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆƽâ°æ can support your business.
Bristol-Myers Squibb, & U.S. Securities and Exchange Commission. (February 11, 2026). Bristol-Myers Squibb's leading products based on revenue from 2023 to 2025 (in million U.S. dollars) [Graph]. In ÌÇÐÄÆƽâ°æ. Retrieved July 30, 2026, from /statistics/266585/bristol-myers-squibbs-top-products-based-on-revenue/
Bristol-Myers Squibb, und U.S. Securities and Exchange Commission. "Bristol-Myers Squibb's leading products based on revenue from 2023 to 2025 (in million U.S. dollars)." Chart. February 11, 2026. ÌÇÐÄÆƽâ°æ. Accessed July 30, 2026. /statistics/266585/bristol-myers-squibbs-top-products-based-on-revenue/
Bristol-Myers Squibb, U.S. Securities and Exchange Commission. (2026). Bristol-Myers Squibb's leading products based on revenue from 2023 to 2025 (in million U.S. dollars). ÌÇÐÄÆƽâ°æ. ÌÇÐÄÆƽâ°æ Inc.. Accessed: July 30, 2026. /statistics/266585/bristol-myers-squibbs-top-products-based-on-revenue/
Bristol-Myers Squibb, and U.S. Securities and Exchange Commission. "Bristol-myers Squibb's Leading Products Based on Revenue from 2023 to 2025 (in Million U.S. Dollars)." ÌÇÐÄÆƽâ°æ, ÌÇÐÄÆƽâ°æ Inc., 11 Feb 2026, /statistics/266585/bristol-myers-squibbs-top-products-based-on-revenue/
Bristol-Myers Squibb & U.S. Securities and Exchange Commission, Bristol-Myers Squibb's leading products based on revenue from 2023 to 2025 (in million U.S. dollars) ÌÇÐÄÆƽâ°æ, /statistics/266585/bristol-myers-squibbs-top-products-based-on-revenue/ (last visited July 30, 2026)
Bristol-Myers Squibb's leading products based on revenue from 2023 to 2025 (in million U.S. dollars) [Graph], Bristol-Myers Squibb, & U.S. Securities and Exchange Commission, February 11, 2026. [Online]. Available: /statistics/266585/bristol-myers-squibbs-top-products-based-on-revenue/
